ANI Pharmaceuticals (ANIP) FY 2025 earnings snapshot

ANI Pharmaceuticals (ANIP) just wrapped up FY 2025 with Q4 revenue of US$247.1 million and basic EPS of US$1.23, capping a year in which trailing twelve month revenue reached US$883.4 million and basic EPS came in at US$3.50. Over recent quarters, revenue has moved from US$190.6 million in Q4 2024 to US$247.1 million in Q4 2025, while quarterly basic EPS shifted from a loss of US$0.55 to a profit of US$1.23, pointing to a very different earnings profile than a year ago. For investors, the key question now is how durable these improved margins and profitability levels look as one off items roll out of the numbers.

See our full analysis for ANI Pharmaceuticals.

With the headline figures in place, the next step is to see how these results line up with the widely held narratives about ANI Pharmaceuticals, and where the numbers may challenge those stories.

Profitability swings from loss to US$70.2 million in a year

• On a trailing 12 month basis, net income moved from a loss of US$20.1 million in Q4 2024 to a profit of US$70.2 million by Q4 2025, with quarterly net income excluding extra items at US$25.4 million in Q4 2025 compared with a loss of US$10.7 million in Q4 2024.
• Consensus narrative emphasizes a multiyear growth story around Cortrophin Gel and higher value drugs, and this sharp swing into profitability lines up with that, but:
  • Trailing Basic EPS over the last year sits at US$3.50, after negative trailing EPS of US$1.04 in Q4 2024, which fits the idea of a business leaning more on rare disease and complex products.
  • At the same time, a US$30.6 million one off gain fed into these trailing earnings, so part of this jump is not from ongoing operations, which is something the consensus view needs to factor in when talking about “sustained” margin improvement.

P/E of 27.2x vs peers at 12.8x

• The trailing P/E of 27.2x sits well above both the peer average of 12.8x and the US Pharmaceuticals industry average of 16.7x, while the current share price of US$83.91 is below the cited DCF fair value of US$365.71 and the analyst consensus target of US$110.63.
• Bulls argue the premium multiple is justified by higher earnings growth and rare disease potential, and the numbers partly support that but also raise questions:
  • Trailing earnings growth is framed at 44.2% per year over five years with earnings forecast to grow about 24.8% a year, which helps explain why some investors are comfortable with a P/E above the 16.7x industry level.
  • However, because the last 12 months include that US$30.6 million one off gain, the 27.2x multiple is based on earnings that are temporarily boosted, so anyone leaning on the DCF fair value of US$365.71 or the US$110.63 target will likely want to think about what valuation looks like without that extra help.

Bulls point to rare disease growth, high forecast earnings expansion, and a big gap to estimated value, so if you want to see how that story hangs together in detail, 🐂 ANI Pharmaceuticals Bull Case

One off gain complicates the bearish margin story

• Over the last 12 months, ANI’s reported earnings were materially affected by a US$30.6 million one time gain, while trailing revenue over the same period reached US$883.4 million and quarterly net income excluding extra items in 2025 moved from US$7.3 million in Q2 to US$25.4 million in Q4.
• Bears focus on earnings risk from product concentration and pricing pressure, and the recent figures both support and challenge that concern:
  • Critics highlight reliance on specialty products like Cortrophin Gel and exposure to generics price pressure, and the need for a one off gain to lift trailing earnings fits with the idea that underlying profit can be sensitive to those headwinds.
  • On the other hand, even stripping out extras, quarterly net income excluding extra items is positive across all four 2025 quarters, which pushes back a bit against the view that profitability depends entirely on that one gain, although it does not remove the sensitivity to future pricing or reimbursement shifts.

Skeptics worry that margins rest on fragile footing, so it helps to see exactly how product mix, competition, and pricing risks show up in the full bear case before drawing conclusions, 🐻 ANI Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ANI Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and concern feels familiar, that is because the story clearly has two sides. Review the full picture now and see what stands out to you in the 4 key rewards and 3 important warning signs

See What Else Is Out There

ANI Pharmaceuticals’ earnings currently lean on a US$30.6 million one off gain and a high 27.2x P/E, which raises questions about underlying value and durability.

If that reliance on temporary boosts and a premium multiple makes you cautious, it may be a good time to compare with companies in the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.